TOURMALINE-AL1 trial, a phase III, randomized clinical trial evaluating the effect of Ninlaro (ixazomib) in combination with dexamethasone, did not meet the first of the two primary endpoints of significant improvement in overall hematologic response in patients with relapsed or refractory systemic light-chain amyloidosis.
MacroGenics Inc. has presented updated results from the phase III SOPHIA study comparing margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer who have previously been treated with anti-HER2-targeted therapies.
Keytruda (pembrolizumab) showed improvements in overall survival, progression-free survival and objective response rate as monotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer whose tumors expressed PD-L1 (tumor proportion score [TPS] ≥1%), regardless of KRAS mutational status.
For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients' bodies, a study led by Dana-Farber Cancer Institute researchers suggests.
A study finds more than two-fold differences between counties with the lowest and highest rates of surgery for patients with early stage lung cancer, with socioeconomic and healthcare delivery factors contributing to the gap. The study appears in Chest.
The phase III IMbrave150 study evaluating Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) demonstrated statistically significant and clinically meaningful improvements in overall survival and progression-free survival compared with sorafenib in people with unresectable hepatocellular carcinoma who have not received prior systemic therapy.
The phase III ALTA-1L trial evaluating Alunbrig (brigatinib) versus crizotinib in adults with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer who had not received a prior ALK inhibitor demonstrated reduced risk of disease progression or death.
City of Hope researchers found kidney cancer patients who had already tried two or three different treatments had improved chances of preventing cancer progression with an experimental drug, Fotivda (tivozanib), compared to an alternative approved by FDA.
Duke Cancer Institute researchers have observed how stem cell mutations quietly arise and spread throughout a widening field of the colon until they eventually predominate and become a malignancy.
Men who seek treatment at a multidisciplinary prostate cancer clinic are more likely to be advised about treatment choices and to receive care that complies with evidence-based treatment guidelines, an MD Anderson Cancer Center study found.
